Real-world effectiveness of erenumab in migraine

Key clinical point: Erenumab 70 mg was effective for the treatment of high-frequency episodic migraine (HFEM) or chronic migraine (CM) in a real-world setting.

Major finding: Erenumab was effective with a rapid progressive decrease in monthly migraine days (week 12: HEFM, 4.5 days; CM, 9.3 days). More than 50% of HEFM and 75% of CM patients responded to the treatment.

Study details: The data come from a real-life prospective cohort study of 372 patients affected by HEFM or CM with 3 or more prior preventive therapeutic failures.

Disclosures: This work was partially supported by the Italian Ministry of Health (Institutional Funding Ricerca Corrente). C Altamura, N Brunelli, A Fallacara, CM Costa, D Santangelo, A Salerno, B Mercuri, and A Carnevale declared no conflicts of interest. The remaining authors reported ties with various institutions and/or pharmaceutical companies.

Source: Barbanti P et al. Headache. 2020 Dec 18. doi: 10.1111/head.14032.

Key clinical point: Erenumab 70 mg was effective for the treatment of high-frequency episodic migraine (HFEM) or chronic migraine (CM) in a real-world setting.

Major finding: Erenumab was effective with a rapid progressive decrease in monthly migraine days (week 12: HEFM, 4.5 days; CM, 9.3 days). More than 50% of HEFM and 75% of CM patients responded to the treatment.

Study details: The data come from a real-life prospective cohort study of 372 patients affected by HEFM or CM with 3 or more prior preventive therapeutic failures.

Disclosures: This work was partially supported by the Italian Ministry of Health (Institutional Funding Ricerca Corrente). C Altamura, N Brunelli, A Fallacara, CM Costa, D Santangelo, A Salerno, B Mercuri, and A Carnevale declared no conflicts of interest. The remaining authors reported ties with various institutions and/or pharmaceutical companies.

Source: Barbanti P et al. Headache. 2020 Dec 18. doi: 10.1111/head.14032.

Key clinical point: Erenumab 70 mg was effective for the treatment of high-frequency episodic migraine (HFEM) or chronic migraine (CM) in a real-world setting.

Major finding: Erenumab was effective with a rapid progressive decrease in monthly migraine days (week 12: HEFM, 4.5 days; CM, 9.3 days). More than 50% of HEFM and 75% of CM patients responded to the treatment.

Study details: The data come from a real-life prospective cohort study of 372 patients affected by HEFM or CM with 3 or more prior preventive therapeutic failures.

Disclosures: This work was partially supported by the Italian Ministry of Health (Institutional Funding Ricerca Corrente). C Altamura, N Brunelli, A Fallacara, CM Costa, D Santangelo, A Salerno, B Mercuri, and A Carnevale declared no conflicts of interest. The remaining authors reported ties with various institutions and/or pharmaceutical companies.

Source: Barbanti P et al. Headache. 2020 Dec 18. doi: 10.1111/head.14032.